Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SBBP

Strongbridge Biopharma (SBBP) Stock Price, News & Analysis

Strongbridge Biopharma logo

About Strongbridge Biopharma Stock (NASDAQ:SBBP)

Advanced Chart

Key Stats

Today's Range
$1.95
$2.06
50-Day Range
$1.89
$2.29
52-Week Range
$1.85
$4.26
Volume
684,684 shs
Average Volume
866,464 shs
Market Capitalization
$135.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Receive SBBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBBP Stock News Headlines

Matinas BioPharma Holdings Inc (MTNB)
Lytix Biopharma As Share Price (LYTIX.OL)
Trump Knows Exactly What He’s Doing…
With Trump in office, new money is flowing in and out of the market like never before... And some folks using my strategy are making a fast fortune... no matter which way the market moves. This is the same one-ticker strategy I used to make more $95 million in verified profits for my clients during the 2008 financial crisis. But now... with Trump sending about $240 billon into the markets every week on specific, pre-determined dates...
Ambrx Biopharma Inc AMAM
HILS Hillstream BioPharma, Inc.
ABUS - Arbutus Biopharma Corporation
The Nominees for Best Biopharma CEO of 2015 Are...
See More Headlines

SBBP Stock Analysis - Frequently Asked Questions

Strongbridge Biopharma plc (NASDAQ:SBBP) announced its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The biotechnology company earned $10.04 million during the quarter, compared to analyst estimates of $8.83 million. Strongbridge Biopharma had a negative net margin of 115.67% and a negative trailing twelve-month return on equity of 66.82%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Strongbridge Biopharma investors own include Energy Transfer (ET), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
8/05/2021
Today
6/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBBP
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.08 million
Net Margins
-115.67%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$30.73 million
Price / Cash Flow
N/A
Book Value
$0.98 per share
Price / Book
2.04

Miscellaneous

Free Float
N/A
Market Cap
$135.66 million
Optionable
Optionable
Beta
1.58

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:SBBP) was last updated on 6/28/2025 by MarketBeat.com Staff
From Our Partners